05:44 PM EDT, 10/21/2025 (MT Newswires) -- Alector ( ALEC ) said Tuesday that its Phase 3 trial of latozinemab in frontotemporal dementia caused by a progranulin gene mutation failed to meet its primary clinical endpoint.

The company will halt the continuation study for latozinemab and reduce its workforce by 49%. Sara Kenkare-Mitra, president and head of research and development, resigned effective Dec. 22.

The 96-week INFRONT-3 trial showed no slowing of disease progression, although the treatment achieved a biomarker effect on plasma progranulin levels, the company said. Latozinemab was developed in collaboration with GSK (GSK).

Alector ( ALEC ) said it had $291 million in cash as of Sept. 30, providing runway through 2027.

The company's shares fell 50% in after-hours trading.